Estimated life expectancy of Parkinson’s patients compared with the UK population
Identifieur interne : 000B70 ( Main/Corpus ); précédent : 000B69; suivant : 000B71Estimated life expectancy of Parkinson’s patients compared with the UK population
Auteurs : Lianna S. Ishihara ; Anne Cheesbrough ; Carol Brayne ; Anette SchragSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2007-12.
Abstract
Objective: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. Methods: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Results: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. Conclusions: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.
Url:
DOI: 10.1136/jnnp.2006.100107
Links to Exploration step
ISTEX:6A9B62154B5B05120C6BAC98AC6C9BB315973B53Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Estimated life expectancy of Parkinson’s patients compared with the UK population</title><author><name sortKey="Ishihara, Lianna S" sort="Ishihara, Lianna S" uniqKey="Ishihara L" first="Lianna S" last="Ishihara">Lianna S. Ishihara</name><affiliation><mods:affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Cheesbrough, Anne" sort="Cheesbrough, Anne" uniqKey="Cheesbrough A" first="Anne" last="Cheesbrough">Anne Cheesbrough</name><affiliation><mods:affiliation>GlaxoSmithKline, Stockley Park, UK</mods:affiliation></affiliation></author><author><name sortKey="Brayne, Carol" sort="Brayne, Carol" uniqKey="Brayne C" first="Carol" last="Brayne">Carol Brayne</name><affiliation><mods:affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University College London, London, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6A9B62154B5B05120C6BAC98AC6C9BB315973B53</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1136/jnnp.2006.100107</idno><idno type="url">https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B70</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Estimated life expectancy of Parkinson’s patients compared with the UK population</title><author><name sortKey="Ishihara, Lianna S" sort="Ishihara, Lianna S" uniqKey="Ishihara L" first="Lianna S" last="Ishihara">Lianna S. Ishihara</name><affiliation><mods:affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Cheesbrough, Anne" sort="Cheesbrough, Anne" uniqKey="Cheesbrough A" first="Anne" last="Cheesbrough">Anne Cheesbrough</name><affiliation><mods:affiliation>GlaxoSmithKline, Stockley Park, UK</mods:affiliation></affiliation></author><author><name sortKey="Brayne, Carol" sort="Brayne, Carol" uniqKey="Brayne C" first="Carol" last="Brayne">Carol Brayne</name><affiliation><mods:affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, University College London, London, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2007-12">2007-12</date><biblScope unit="volume">78</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1304">1304</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">6A9B62154B5B05120C6BAC98AC6C9BB315973B53</idno><idno type="DOI">10.1136/jnnp.2006.100107</idno><idno type="href">jnnp-78-1304.pdf</idno><idno type="ArticleID">jn100107</idno><idno type="PMID">17400591</idno><idno type="local">jnnp;78/12/1304</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. Methods: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Results: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. Conclusions: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>Lianna S Ishihara</name><affiliations><json:string>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</json:string></affiliations></json:item><json:item><name>Anne Cheesbrough</name><affiliations><json:string>GlaxoSmithKline, Stockley Park, UK</json:string></affiliations></json:item><json:item><name>Carol Brayne</name><affiliations><json:string>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</json:string></affiliations></json:item><json:item><name>Anette Schrag</name><affiliations><json:string>Department of Clinical Neurosciences, University College London, London, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Papers</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>JNNP Patients' choice</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Objective: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. Methods: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Results: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. Conclusions: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.</abstract><qualityIndicators><score>7.41</score><pdfVersion>1.2</pdfVersion><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>2</keywordCount><abstractCharCount>1697</abstractCharCount><pdfWordCount>4410</pdfWordCount><pdfCharCount>27764</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>298</abstractWordCount></qualityIndicators><title>Estimated life expectancy of Parkinson’s patients compared with the UK population</title><pmid><json:string>17400591</json:string></pmid><genre><json:string>research-article</json:string></genre><host><volume>78</volume><pages><first>1304</first></pages><issn><json:string>0022-3050</json:string></issn><issue>12</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-330X</json:string></eissn><title>Journal of Neurology, Neurosurgery & Psychiatry</title></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1136/jnnp.2006.100107</json:string></doi><id>6A9B62154B5B05120C6BAC98AC6C9BB315973B53</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Estimated life expectancy of Parkinson’s patients compared with the UK population</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>BMJ Publishing Group Ltd</publisher><availability><p>BMJ</p></availability><date>2007-03-30</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Estimated life expectancy of Parkinson’s patients compared with the UK population</title><author><persName><forename type="first">Lianna S</forename><surname>Ishihara</surname></persName><affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</affiliation></author><author><persName><forename type="first">Anne</forename><surname>Cheesbrough</surname></persName><affiliation>GlaxoSmithKline, Stockley Park, UK</affiliation></author><author><persName><forename type="first">Carol</forename><surname>Brayne</surname></persName><affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</affiliation></author><author><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><affiliation>Department of Clinical Neurosciences, University College London, London, UK</affiliation></author></analytic><monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="pISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2007-12"></date><biblScope unit="volume">78</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1304">1304</biblScope></imprint></monogr><idno type="istex">6A9B62154B5B05120C6BAC98AC6C9BB315973B53</idno><idno type="DOI">10.1136/jnnp.2006.100107</idno><idno type="href">jnnp-78-1304.pdf</idno><idno type="ArticleID">jn100107</idno><idno type="PMID">17400591</idno><idno type="local">jnnp;78/12/1304</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007-03-30</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Objective: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. Methods: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Results: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. Conclusions: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.</p></abstract><textClass><keywords scheme="keyword"><list><head>hwp-journal-coll</head><item><term>JNNP Patients' choice</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-03-30">Created</change><change when="2007-12">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id><journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id><journal-id journal-id-type="publisher-id">jnnp</journal-id><journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title><abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title><issn pub-type="ppub">0022-3050</issn><issn pub-type="epub">1468-330X</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jn100107</article-id><article-id pub-id-type="doi">10.1136/jnnp.2006.100107</article-id><article-id pub-id-type="other">jnnp;78/12/1304</article-id><article-id pub-id-type="other">jnnp;jnnp.2006.100107</article-id><article-id pub-id-type="pmid">17400591</article-id><article-id pub-id-type="other">1304</article-id><article-id pub-id-type="other">jnnp.2006.100107</article-id><article-categories><subj-group subj-group-type="heading"><subject content-type="original">Papers</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>JNNP Patients' choice</subject></subj-group></article-categories><title-group><article-title>Estimated life expectancy of Parkinson’s patients compared with the UK population</article-title><alt-title alt-title-type="running-head">Parkinson’s life expectancy</alt-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ishihara</surname><given-names>Lianna S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cheesbrough</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Brayne</surname><given-names>Carol</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Schrag</surname><given-names>Anette</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</addr-line> </aff><aff id="aff2"><label>2</label><addr-line>GlaxoSmithKline, Stockley Park, UK</addr-line> </aff><aff id="aff3"><label>3</label><addr-line>Department of Clinical Neurosciences, University College London, London, UK</addr-line> </aff><author-notes><corresp>Dr Anette Schrag, University Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill St, London NW3 2PF, UK; <email xlink:type="simple">a.schrag@medsch.ucl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2007</year></pub-date><pub-date pub-type="epub-original"><day>30</day><month>3</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>30</day><month>3</month><year>2007</year></pub-date><volume>78</volume><volume-id pub-id-type="other">78</volume-id><volume-id pub-id-type="other">78</volume-id><issue>12</issue><issue-id pub-id-type="other">jnnp;78/12</issue-id><issue-id pub-id-type="other">12</issue-id><issue-id pub-id-type="other">78/12</issue-id><fpage>1304</fpage><history><date date-type="received"><day>15</day><month>6</month><year>2006</year></date><date date-type="rev-recd"><day>8</day><month>2</month><year>2007</year></date><date date-type="accepted"><day>1</day><month>3</month><year>2007</year></date></history><permissions><copyright-statement>2007 BMJ Publishing Group Ltd</copyright-statement><copyright-year>2007</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-78-1304.pdf"></self-uri><abstract><sec><title>Objective:</title><p>To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD.</p></sec><sec><title>Methods:</title><p>A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003.</p></sec><sec><title>Results:</title><p>Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years.</p></sec><sec><title>Conclusions:</title><p>The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.</p></sec></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Estimated life expectancy of Parkinson’s patients compared with the UK population</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Estimated life expectancy of Parkinson’s patients compared with the UK population</title></titleInfo><name type="personal"><namePart type="given">Lianna S</namePart><namePart type="family">Ishihara</namePart><affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anne</namePart><namePart type="family">Cheesbrough</namePart><affiliation>GlaxoSmithKline, Stockley Park, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carol</namePart><namePart type="family">Brayne</namePart><affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><affiliation>Department of Clinical Neurosciences, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><genre>hwp-journal-coll</genre><topic>JNNP Patients' choice</topic></subject><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2007-12</dateIssued><dateCreated encoding="w3cdtf">2007-03-30</dateCreated><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Objective: To calculate the best possible estimates for age specific life expectancy (LE) and anticipated age at the time of death (AAD) in patients with Parkinson’s disease (PD) compared with the general population in the UK. These may be of greater value to patients than standardised mortality ratios (SMRs), which are usually reported in studies on mortality in PD. Methods: A literature review identified articles with data on age stratified life expectancy or SMRs to calculate estimations of LE using the Gompertz function and data on mortality and LE in the UK from the Office of National Statistics and Actuarial Department for the year 2003. Results: Two UK studies and four from Western Europe were used to estimate LE and AAD for patients with PD from SMRs. The mean LEs of patients with PD compared with the general population were: 38 (SD 5) years for onset between 25 and 39 years compared with 49 (SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) years; and 5 (SD 4) years for onset age ⩾65 years compared with 9 (SD 5) years. The average AAD of patients with PD with onset between 25 and 39 years was 71 (SD 3) years and considerably lower than that of the general population (82 (SD 2) years). The difference between average AAD for older individuals with PD (onset ⩾65 years) and the general population was smaller, with an AAD of approximately 88 (SD 7) years compared with 91 (SD 5) years. Conclusions: The calculations showed that LE and AAD in PD are reduced for all onset ages but this reduction is greatest in individuals with a young onset. While the results are average estimates, these can provide useful indications of LE and AAD.</abstract><relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0022-3050</identifier><identifier type="eISSN">1468-330X</identifier><identifier type="PublisherID">jnnp</identifier><identifier type="PublisherID-hwp">jnnp</identifier><identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1304</start></extent></part></relatedItem><identifier type="istex">6A9B62154B5B05120C6BAC98AC6C9BB315973B53</identifier><identifier type="DOI">10.1136/jnnp.2006.100107</identifier><identifier type="href">jnnp-78-1304.pdf</identifier><identifier type="ArticleID">jn100107</identifier><identifier type="PMID">17400591</identifier><identifier type="local">jnnp;78/12/1304</identifier><accessCondition type="use and reproduction" contentType="copyright">2007 BMJ Publishing Group Ltd</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/6A9B62154B5B05120C6BAC98AC6C9BB315973B53/annexes/jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B70 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B70 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:6A9B62154B5B05120C6BAC98AC6C9BB315973B53
|texte= Estimated life expectancy of Parkinson’s patients compared with the UK population
}}
| This area was generated with Dilib version V0.6.23. |  |